Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Boston, MA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $12 billion and a profit of $4.0 billion (its filed statements).
vs its business-model standard
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2834, Pharmaceutical Preparations); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 7.0 out of ten, 9 of 9 metrics filed: past 7.2 out of ten, present 7.7 out of ten, future 5.9 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
- Surviving crises (past): 5.0 out of ten. 1 warning event since 2017; the latest 2019-09-17. 50th percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Track record (past): 8.4 out of ten. +24.2% a year over 10 filed years; profitable in 8 of 10. 84th percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Shareholder treatment (past): 8.0 out of ten. Share count shrank 0.1% a year. 54% of cash flow returned. Insiders: 94 sales, 0 purchases. 80th percentile among 80 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Financial health (present): 7.8 out of ten. ROE 21%: 21¢ of profit per shareholder dollar. Leverage 27%: owes 27¢ per asset dollar. 78th percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Industry position (present): 8.0 out of ten. top 20% of 314 in its family; net margin 32.9%. 80th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Leadership (present): 6.9 out of ten. top 31% of 315 in its family for leadership; chief executive since 2020. 69th percentile among 315 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
- Room to expand (future): 6.0 out of ten. top 40% of 272 in its family for room to expand. 60th percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Growth drivers (future): 5.8 out of ten. top 42% of 307 in its family for growth drivers. 58th percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Expectations vs reality (future): 5.9 out of ten. top 41% of 234 in its family for expectations against reality. 59th percentile among 234 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-02-13 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-04 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-03 (on EDGAR). Newest filing: Form 4, 2026-09-10. Filings on record since 1995. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: TRIKAFTAKAFTRIO 85%, ALYFTREK 7%, Manufactured Product Other 7%, CASGEVY 1%, JOURNAVX 1%, Collaborative and Royalty under 1%. By geography: United States 63%, Europe 29%, Other 8%. As tagged in its annual report (Form 10-K, filed 2026-02-13).
Who runs it
Kewalramani, Reshma (CEO & President); Leiden, Jeffrey M (Executive Chairman); Arbuckle, Stuart A (EVP, COO); Ambrose, Kristen (SVP & Chief Accounting Officer); Sachdev, Amit (EVP Chief Patient & Ext Af Off); Tatsis, Ourania (EVP, Chief Reg. & Quality Off.); Mckechnie, Duncan (EVP, Chief Commercial Officer); Liu, Joy (EVP and Chief Legal Officer); Bunnage, Mark E. (EVP, Chief Scientific Officer); Atkinson, Edward Morrow III (EVP, Chief Technical Ops. Off.); and 14 more. 24 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
This file: Overview · Past · Present · Future · Filings · every company on file
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.